"将'炒至表面微黄''嗅到固有香气逸出'等经验性描述，尝试通过标准色卡比对颜色，用电子鼻、电子舌捕捉 气味和味道的特征信号，把'感觉'变成可测量、可重复的参数或范围。"汪坤介绍，用现代技术为传统技 艺"画像"和"建档"，系统性地用影像、数据记录下老药工的关键操作过程和判断节点，建立数字化经验库， 实现传统技艺的"标准传承"。 赵旭还带领团队挖掘古文献和地方特色，将小米煮天麻炮制技术等传统技艺，结合现代技术开展科学研究， 让这些技艺更标准、更高效；探索建立"挖掘—科研—转化—应用"机制，开发特色制剂保光清凉散，将秘方 转化为安全、有效、质量可控的标准化制剂。 "你看我用指尖在厚朴上轻划一下，通过看划痕可以初步判断它的油性。"2月11日，在河南省中医院全国老药 工传承工作室，全国老药工传承工作室建设项目专家、河南省中医院副院长赵旭正在给学生讲解如何鉴定厚 朴的品质。 这道简单划痕，其实凝聚了赵旭摸索近40年的药材鉴别"语言"。他总结出一套完整的药材鉴别方法：观、 触、嗅、尝、悟，看颜色、摸质地、闻气味、尝味道，最后把所有这些感官信息在心里合一起，综合判断一 味药的真伪优劣。 "药是治病救人的，一丝马虎都不能有。要 ...

Summary of China Traditional Chinese Medicine (CTCM) Conference Call Company Overview - **Company**: China Traditional Chinese Medicine (CTCM) - **Industry**: Traditional Chinese Medicine Key Financial Highlights - **Special Dividend**: CTCM announced a special dividend of RMB 0.32 per share, totaling RMB 798 million, amounting to RMB 402 million in total [2][3] - **Revenue**: For 2024, CTCM reported revenue of approximately RMB 8.807 billion, with a gross margin of 18.69%, a decrease of 3.6 percentage points year-on-year [3] - **Net Profit**: Net profit was approximately RMB 20.07 million, a decline compared to the previous year [3] - **Assets and Liabilities**: As of the end of 2024, current assets were RMB 18.84 billion, down 5% from the end of 2023. Total assets were RMB 31.06 billion, with total liabilities reduced to RMB 10.03 billion [2][3] Business Segment Performance - **Chinese Medicine Production**: Growth observed in Chinese medicine production, Chinese medicine formula granules, and the health sector. The Chinese medicine hospital segment grew by 13% year-on-year, while the Chinese patent medicine segment showed significant growth [2][3] - **Chinese Patent Medicine Sales**: Sales in the Chinese patent medicine segment were approximately RMB 4.53 billion, accounting for 20.6% of total revenue, with a gross margin of 36% [2][5] - **Health Products**: The health product segment expanded through an integrated online and offline operational model, operating 30 stores with significant sales growth [2][5] Strategic Initiatives - **Reform and Compliance**: CTCM aims to deepen reforms and strengthen compliance, focusing on talent development, resource optimization, and production efficiency [2][6] - **Market Strategy**: The company plans to enhance brand differentiation, improve marketing efforts, and modernize governance structures to boost competitiveness and achieve sustainable development [2][6] - **2025 Strategic Focus**: CTCM will emphasize high-quality development in the health sector, integrating core industries and enhancing modernization, technology, globalization, and standardization [7] Market Challenges and Responses - **Volume-based Procurement**: The company faces challenges from volume-based procurement policies, with market share in some provinces around 18%, potentially reaching 30% when considering non-executing regions [2][10] - **Cost Control**: CTCM is implementing strategies to optimize existing industrial layouts, reduce costs, and improve management performance through internal collaboration and technological improvements [2][17] Research and Development - **Innovation Initiatives**: CTCM is enhancing its R&D capabilities, establishing collaborative mechanisms, and focusing on the integration of traditional and modern medicine [9][30] - **New Product Development**: The company has launched new products and is conducting clinical tests to enhance market competitiveness [5][26] Future Outlook - **Market Trends**: The company is optimistic about the long-term prospects of the traditional Chinese medicine industry, despite short-term uncertainties due to policy changes [23][31] - **Focus on High-End Markets**: CTCM plans to concentrate on high-end and profitable segments, particularly in the health industry, while seeking to unify market strategies across the nation [28] Additional Considerations - **Management Structure**: CTCM is optimizing its headquarters management structure to better support business segments and enhance decision-making processes [8] - **Executive Compensation**: Executive compensation is linked to market performance, with ongoing evaluations regarding share buyback strategies [18] This summary encapsulates the key points from the conference call, highlighting the financial performance, strategic initiatives, market challenges, and future outlook of China Traditional Chinese Medicine.